MRNA Company Profile and Key Details

Q: Who are the executives of MRNA?

Mr. Stephane BancelChief Executive Officer & DirectorMr. Juan AndresPres of Strategic Partnerships & Enterprise ExpansionDr. Jerh Collins Ph.D.Chief Technical Operations & Quality OfficerDr. John V. W. Reynders Ph.D.Chief Information OfficerMr. James M. MockChief Financial OfficerMs. Lavina Talukdar CFASenior Vice President & Head of Investor RelationsDr. Stephen Hoge M.D.PresMr. Brad MillerChief Information OfficerDr. Melissa J. Moore Ph.D.Chief Scientific Officer & Member of Scientific Advisory BoardMs. Arpa GarayChief Commercial OfficerColleen HusseySenior Director of Corporation CommunicationsMs. Shannon Thyme KlingerChief Legal Officer & Corporation Sec.

NASDAQ : MRNA

Moderna

$54.42

-1.32-2.37%

Open: 10:44 AM

63.84

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Moderna, Inc. (MRNA) stock declined over -2.37%, trading at $54.42 on NASDAQ, down from the previous close of $55.74. The stock opened at $55.03, fluctuating between $52.65 and $56.16 in the recent session.

Stock Snapshot

55.74

Prev. Close

21.49B

Market Cap

52.65

Day Low

-7.5

P/E Ratio

-7.26

EPS (TTM)

-10.04

Cash Flow per Share

55.03

Open

394.94M

Number of Shares

56.1616

Day High

93.37%

Free Float in %

36.36

Book Value

2.39M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 09, 2026	53.30	56.62	51.91	55.74	13.11M
Mar 06, 2026	52.22	52.77	49.22	52.52	12.22M
Mar 03, 2026	50.45	51.86	48.09	49.83	8.59M
Mar 02, 2026	52.42	54.94	50.45	52.85	9.38M
Feb 27, 2026	51.27	53.62	50.73	53.57	9.05M
Feb 26, 2026	51.43	52.81	50.62	51.71	5.75M
Feb 25, 2026	50.75	53.85	50.67	51.37	7.94M
Feb 24, 2026	50.18	51.97	49.53	50.52	6.98M
Feb 23, 2026	48.70	54.02	48.68	50.29	11.13M
Feb 20, 2026	49.16	50.48	48.29	49.87	9.01M
Feb 19, 2026	46.99	50.46	45.80	49.70	12.1M
Feb 18, 2026	46.69	47.68	45.66	46.60	13.07M
Feb 17, 2026	42.28	45.07	41.97	43.93	10.42M
Feb 13, 2026	41.85	44.80	41.20	42.23	16.31M
Feb 12, 2026	40.12	40.91	38.82	40.11	7.87M
Feb 11, 2026	37.60	40.81	36.66	40.51	14.87M
Feb 10, 2026	42.87	45.50	41.68	42.00	9.63M
Feb 09, 2026	41.07	42.00	40.17	41.95	6.29M
Feb 06, 2026	41.18	41.49	39.50	41.01	8.33M
Feb 05, 2026	42.03	43.85	40.08	40.87	11.6M

Contact Details

Cambridge, MA 02139

United States

https://www.modernatx.com 617 714 6500

About Company

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Peers

REGN

21.74+2.86%

Regeneron Pharmaceuticals, Inc.$781.60 ARGX

22.6+3.15%

argenx SE$740.40 UTHR

51.01+10.67%

United Therapeutics Corporation$529.17 VRTX

4.18+0.92%

Vertex Pharmaceuticals Incorporated$460.87 MDGL

0.37+0.09%

Madrigal Pharmaceuticals, Inc.$433.20 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

2.93+0.91%

Alnylam Pharmaceuticals, Inc.$323.59 PRAX

-1.7-0.55%

Praxis Precision Medicines, Inc.$309.01 KRYS

4.96+1.96%

Krystal Biotech, Inc.$258.65 ASND

-0.73-0.30%

Ascendis Pharma A/S$239.92

Company Overview

Moderna, Inc. (NASDAQ:MRNA) closed at $54.42 USD, losing -$1.32 (-2.37%) from the previous close of $55.74. The stock is currently mid-range between its 52-week high and low $22.28 and $59.55. With a market capitalization of about $21.49 billion, Moderna, Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.35). Key stats such as the average daily volume over the past year has been around 12.11 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Moderna, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Stéphane Bancel, the company employs approximately 5,800 people and listed since December 07, 2018. Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.

Technical Performance

MRNA has shown sold momentum, gaining 27.07% over the past week and 65.32% over the past quarter, though year-to-date performance is up 45.81%. Short-term trend indicators are bearishly aligned (SMA20 14.77%, SMA50 28.73%, SMA200 70.77%). The stock’s 14-day RSI is 71.7 (overbought), while the ATR of 3.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.32% below its high and over 132.09% above its low. Average 10-day trading volume of 10.83 million shares is in line with the 3-month average of 11.64 million, indicating normal recent market interest.

Valuation Metrics

Moderna, Inc. trades at a P/E ratio of -7.52, slightly below the S&P 500 average, with a price-to-sales ratio of 11.0 and a price-to-book ratio of 2.45 suggesting the stock is closer to book value. The P/FCF stands at -10.4, also below market averages.

Dividend & Fair Value

Moderna, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.77. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Moderna, Inc. generated EPS of -$7.26 over the past year. Five-year average earnings growth is -29.93%. Wall Street analysts project EPS growth of 25.94% annually over the next five years. The latest quarter delivered EPS of -$0.51. The next quarter is forecast at -$2.03. Next year's EPS is expected at $46.76. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 13 Hold ratings, 0 Sell rating and 6 Strong Sell ratings. Price targets range from $70.00 to $15.00. The high target offers 25.58% upside. The low target suggests -73.09% downside. The mean target is $34.96. This offers -37.28% upside. Moderna, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by -76.15%. The prior quarter beat by -28.76%. Over the last six quarters, Apple has recorded several small beats. These include -0.6% in August 01, 2024.

Shareholding & Insider Activity

Moderna, Inc. has 394.94 million shares outstanding. The public float is 368.35 million shares, elevated short interest at 22.20% of float. This equals 71.34 million shares. The short ratio is 5.05 days. Institutional investors hold 80.74% of the float. Insiders own 7.24%. Bancel Stephane holds 9.15 million shares, Hoge Stephen has 1.46 million shares and SAGAN PAUL has 312.03 thousand shares. Over the past six months, insider transactions show net selling. They sold 198.25 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Moderna generated $6.75B in revenue, or $17.68 per share. Gross margin was 30.52%, operating margin -62.76%, and net profit margin -69.80%. Returns are negative, with ROA at -25.58% and ROE at -34.03%.
On valuation metrics, Moderna trades at a P/E of -7.52, P/S of 11.00 and P/B of 2.45. The current ratio is 3.29 and quick ratio is 3.22. Operationally, the company’s inventory turnover is 10.91 and cash conversion cycle is -1.30 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.22, supported by a cash flow-to-debt ratio of -0.97.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Moderna posted revenue of $6.75B, down slightly from $19.26B in the prior quarter. Gross profit was $2.06B (margin 30.52%). Operating income was - $4.24B (margin -62.8%). Net income was- $4.71B (EPS - $12.34).
The company ended the quarter with $8.60B in cash and short-term investments, a total debt of $1.24B, and net debt of - $1.66B. Total assets were $18.43B, with equity of $13.85B. Financials further reflected weakness, with operating cash flow of - $3.12B, free cash flow of - $3.83B, and capital expenditures of - $707.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Moderna, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.05%, with price expected at $58.00 by March 23, 2026, within a range of $53.36 to $62.55 3-Month Outlook: Projected rise of 18.96%, reaching $66.31 by June 05, 2026, with a range of $63.78 to $68.44. 1-Year Outlook: Projected loss of -80.48%, with price at $10.88 by March 09, 2027, within a range of $1.76 to $19.05.

Key Takeaways

Moderna, Inc. (NASDAQ:MRNA) shares are up 45.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Moderna, Inc. trading at a premium to the broader market with a P/E of -7.52. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $113.74, suggesting 104.05% upside. Our AI forecast model points to short-term strength (4.05% over two weeks), a medium-term rise (18.96% over three months), and a longer-term loss (-80.48% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Moderna, Inc. (MRNA) stock price?

Moderna, Inc. (NASDAQ: MRNA) stock price is $54.42 in the last trading session. During the trading session, MRNA stock reached the peak price of $56.16 while $52.65 was the lowest point it dropped to. The percentage change in MRNA stock occurred in the recent session was -2.37% while the dollar amount for the price change in MRNA stock was - $1.32.

MRNA's industry and sector of operation?

The NASDAQ listed MRNA is part of Biotechnology industry that operates in the broader Healthcare sector. Moderna, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MRNA?

Mr. Stephane Bancel
Chief Executive Officer & Director
Mr. Juan Andres
Pres of Strategic Partnerships & Enterprise Expansion
Dr. Jerh Collins Ph.D.
Chief Technical Operations & Quality Officer
Dr. John V. W. Reynders Ph.D.
Chief Information Officer
Mr. James M. Mock
Chief Financial Officer
Ms. Lavina Talukdar CFA
Senior Vice President & Head of Investor Relations
Dr. Stephen Hoge M.D.
Pres
Mr. Brad Miller
Chief Information Officer
Dr. Melissa J. Moore Ph.D.
Chief Scientific Officer & Member of Scientific Advisory Board
Ms. Arpa Garay
Chief Commercial Officer
Colleen Hussey
Senior Director of Corporation Communications
Ms. Shannon Thyme Klinger
Chief Legal Officer & Corporation Sec.

How MRNA did perform over past 52-week?

MRNA's closing price is 150.18% higher than its 52-week low of $22.28 where as its distance from 52-week high of $59.55 is -6.4%.

How many employees does MRNA have?

Number of MRNA employees currently stands at 5,800.

Link for MRNA official website?

Official Website of MRNA is: https://www.modernatx.com

How do I contact MRNA?

MRNA could be contacted at phone 617 714 6500 and can also be accessed through its website. MRNA operates from 200 Technology Square, Cambridge, MA 02139, United States.

How many shares of MRNA are traded daily?

MRNA stock volume for the day was 2.39M shares. The average number of MRNA shares traded daily for last 3 months was 12.11M.

What is the market cap of MRNA currently?

The market value of MRNA currently stands at $21.49B with its latest stock price at $54.42 and 394.94M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	5800
Beta	1.35
Sales or Revenue	$6.75B
5Y Sales Change%	10.869%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MRNA Company Profile and Key Details

Moderna

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook